Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Michael H. Davidson to Indoles

This is a "connection" page, showing publications Michael H. Davidson has written about Indoles.

 
Connection Strength
 
 
 
2.474
 
  1. Kirkpatrick B, Saoud JB, Strauss GP, Ahmed AO, Tatsumi K, Opler M, Luthringer R, Davidson M. The brief negative symptom scale (BNSS): Sensitivity to treatment effects. Schizophr Res. 2018 07; 197:269-273.
    View in: PubMed
    Score: 0.587
  2. Davidson M, Saoud J, Staner C, Noel N, Luthringer E, Werner S, Reilly J, Schaffhauser JY, Rabinowitz J, Weiser M, Luthringer R. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017 12 01; 174(12):1195-1202.
    View in: PubMed
    Score: 0.571
  3. Davidson MH, Palmisano J, Wilson H, Liss C, Dicklin MR. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. Clin Ther. 2003 Nov; 25(11):2738-53.
    View in: PubMed
    Score: 0.220
  4. Rabinowitz J, Badescu S, Palamarchuk P, Filyk V, Voloshchuk A, Rud V, Melnyk E, Skrypnikov A, Davidson M, Saoud J, Luthringer R. Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial. Schizophr Res. 2019 09; 211:103-104.
    View in: PubMed
    Score: 0.164
  5. Keefe RSE, Harvey PD, Khan A, Saoud JB, Staner C, Davidson M, Luthringer R. Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. J Clin Psychiatry. 2018 May/Jun; 79(3).
    View in: PubMed
    Score: 0.150
  6. Dujovne CA, Davidson MH. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med. 1994 Jun 06; 96(6A):37S-40S.
    View in: PubMed
    Score: 0.115
  7. Davidson MH. Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety. Am J Med. 1994 Jun 06; 96(6A):41S-44S.
    View in: PubMed
    Score: 0.115
  8. Chen F, Maccubbin D, Yan L, Sirah W, Chen E, Sisk CM, Davidson M, Blomqvist P, McKenney JM. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol. 2013 Jul 15; 167(1):225-31.
    View in: PubMed
    Score: 0.098
  9. Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 01; 104(1):74-81.
    View in: PubMed
    Score: 0.082
  10. Davidson MH. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan; 11(1):67-70.
    View in: PubMed
    Score: 0.079
  11. Paolini JF, Bays HE, Ballantyne CM, Davidson M, Pasternak R, Maccubbin D, Norquist JM, Lai E, Waters MG, Kuznetsova O, Sisk CM, Mitchel YB. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008 Nov; 26(4):547-60.
    View in: PubMed
    Score: 0.078
  12. Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, Ballantyne CM. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 01; 101(5):625-30.
    View in: PubMed
    Score: 0.073
  13. Davidson M. Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Prev Cardiol. 2005; 8(4):244-9.
    View in: PubMed
    Score: 0.060
  14. Davidson MH. Statin trials in progress: unanswered questions. Curr Atheroscler Rep. 2001 Jan; 3(1):9-13.
    View in: PubMed
    Score: 0.045
  15. Koren MJ, Smith DG, Hunninghake DB, Davidson MH, McKenney JM, Weiss SR, Schrott HG, Henley RW, Tresh P, McLain RW, Bakker-Arkema RG, Black DM. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 1998 Jul; 14(1):59-70.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.